| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Glycerol phenylbutyrate |
| Brand | Ravicti® |
| Indication | For use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs). |
| Assessment Process | |
| Rapid review commissioned | 26/03/2018 |
| Rapid review completed | 20/06/2018 |
| Rapid review outcome | A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti®) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. |
The HSE has approved reimbursement; August 2018
